SC
CRSP icon

Shellback Capital’s CRISPR Therapeutics CRSP Stock Holding History

Shellback Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,958
Closed -$3.47M – 128
2024
Q1 		$3.47M Buy
+50,958
New +$3.65M 0.23% 100
2021
Q4 		– Sell
-40,000
Closed -$4.48M – 109
2021
Q3 		$4.48M Buy
40,000
+17,239
+76% +$2.17M 0.26% 80
2021
Q2 		$3.69M Buy
+22,761
New +$2.77M 0.2% 101

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Shellback Capital's CRSP Position: Q2 2024 in Review

Shellback Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 50,958 shares — an estimated $3.47M sold.

Shellback Capital first reported a position in CRSP in Q2 2021 and held it in 3 quarters. The position peaked at $4.48M in Q3 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Shellback Capital reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Shellback Capital sold 50,958 CRISPR Therapeutics shares in Q2 2024, an estimated $3.47M.
  • Shellback Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 3 quarters.
  • Shellback Capital's CRISPR Therapeutics position peaked at $4.48M in Q3 2021.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Shellback Capital's 13F filing for Q2 2024, filed 14 Aug 2024.